VNDA
Vanda Pharmaceuticals Inc
Halal Rating :
Last Price
$4.37
Last updated:
Market Cap
-
7D Change
-3.53%
1 Year Change
15.3%
Company Overview
Industries
Exchange
Next Earnings Date
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies to address high unmet medical needs. Their key products include HETLIOZ® (tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in Smith-Magenis Syndrome, and Fanapt® (iloperidone) for the treatment of schizophrenia.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $47.65m | $58.65m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $50.47m | $60.62m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $47.46m | $56.7m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Vanda Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.